🧪 How to Participate in Psilocybin Research Studies

Understanding ClinicalTrials.gov

ClinicalTrials.gov is the US government's official registry of clinical studies. It contains information on over 400,000 studies worldwide. For anyone interested in participating in psilocybin research, it is the authoritative starting point.

How to Search for Psilocybin Trials

1. Go to clinicaltrials.gov
2. In the search box, enter "psilocybin" or "psilocybin assisted therapy"
3. Filter by "Recruiting" status to find currently enrolling trials
4. Filter by location to find studies near you
5. Click on individual studies to see eligibility criteria, contact information, and study details

As of 2026, dozens of psilocybin trials are actively recruiting in the US, UK, Canada, Australia, and across Europe. New trials open regularly.

Major Research Programs

Johns Hopkins Center for Psychedelic and Consciousness Research

Johns Hopkins (hopkinspsychedelic.org) is among the most productive psilocybin research centers globally. Their research has studied psilocybin for depression, anxiety, addiction (smoking cessation, alcohol use disorder), and in terminally ill patients with existential distress. They publish regularly in major peer-reviewed journals and often have multiple active recruitment protocols.

Imperial College London — Centre for Psychedelic Research

Imperial's Centre for Psychedelic Research (imperial.ac.uk/psychedelic-research-centre) conducts brain imaging studies alongside clinical trials, contributing to fundamental neuroscience of psilocybin. Their 2021 randomized controlled trial comparing psilocybin to escitalopram (SSRI) for depression (published in NEJM) was a landmark in the field.

NYU Langone Center for Psychedelic Medicine

NYU (med.nyu.edu/psychedelic-medicine) has run influential trials on psilocybin for existential distress in cancer patients and alcohol use disorder. Their studies were among the first modern trials to demonstrate sustained antidepressant and anti-addiction effects.

MAPS — Multidisciplinary Association for Psychedelic Studies

While MAPS' primary work has focused on MDMA-assisted therapy, they also support psilocybin research and maintain a network of researchers and trial sites. Their maps.org site has trial listings and research resources.

University of California, Davis and Berkeley

UC Davis and UC Berkeley both have growing psychedelic research programs. Berkeley's Center for the Science of Psychedelics (BCSP) focuses on neuroimaging and consciousness research alongside clinical work.

Typical Eligibility Criteria

Eligibility varies significantly between trials. General patterns include:

Common Inclusion Criteria

• Age 21–65 (varies by study)
• Diagnosis relevant to the study condition (e.g., treatment-resistant depression, alcohol use disorder)
• Ability to give informed consent
• Adequate language fluency for assessments
• Willingness to remain in study location for required visits

Common Exclusion Criteria

• Personal or family history of psychosis or schizophrenia
• Bipolar I disorder
• Certain cardiovascular conditions
• Current use of lithium, MAOIs, or certain other medications
• Active suicidal ideation with plan
• Pregnancy or breastfeeding
• Significant liver or kidney disease

What Participation Involves

A typical psilocybin clinical trial involves:

1. Screening phase: Medical and psychiatric interviews, lab tests, psychological assessments to determine eligibility (may take several weeks)
2. Preparation sessions: 2-4 sessions with trained therapists to prepare for the experience, set intentions, and build therapeutic alliance
3. Psilocybin session(s): 1-3 sessions in a comfortable clinical setting, typically lasting 6-8 hours each, with 2 trained therapists present throughout
4. Integration sessions: Follow-up therapy sessions to process and integrate the experience
5. Follow-up assessments: Questionnaires and interviews at various time points (1 week, 1 month, 6 months post-session)

Total time commitment is typically 3-6 months from enrollment through final follow-up.

Compensation and Rights

Most research trials offer some compensation for participant time and travel. In the US, clinical trial participants have federally protected rights including:

• The right to withdraw from the study at any time without penalty
• The right to be informed of all study procedures and risks before consenting
• Protection of privacy under HIPAA
• Access to study results
• Compensation for research-related injuries in most institution-sponsored trials

Questions to Ask Researchers

• What is the specific research question this study is addressing?
• What dose(s) of psilocybin will I receive?
• Is there a placebo condition? How is blinding handled?
• What support is available during and after sessions?
• What happens if I experience significant distress?
• What are the known and potential risks?
• What are the potential benefits to me?
• Is there financial compensation, and what expenses are covered?
• What happens to my medical data and who has access to it?

FAQ

Do I have to have a mental health condition to participate in psilocybin research?

Not necessarily. Some trials study psilocybin in healthy volunteers for basic science purposes (understanding brain effects, neuroimaging studies). Others focus on specific conditions like depression, addiction, or existential distress. Check individual trial listings on ClinicalTrials.gov for specific eligibility requirements. Healthy volunteer studies are often looking for people with no significant psychiatric history.

Is it safe to participate in a clinical trial?

Psilocybin has a well-established safety profile in research settings. The primary risks are psychological rather than physical, and in clinical trial settings, extensive screening, preparation, and trained support mitigate these substantially. All clinical trials operate under Institutional Review Board (IRB) oversight, which independently reviews the protocol to protect participant welfare. The risk-benefit ratio should be thoroughly discussed with the research team during screening.

Will my participation in a psilocybin trial affect my employment or legal status?

Participation in an FDA-approved clinical trial is legal at the federal level in the US. However, employment drug testing does not distinguish between legal research participation and other use — psilocin (the active metabolite) typically clears from urine within 24-72 hours but may vary. Discuss this with the research team before enrolling if employment drug testing is a concern. Clinical trial participation is protected medical information under HIPAA.

How do I know if a trial is legitimate?

Legitimate psilocybin trials are registered on ClinicalTrials.gov with an NCT number, conducted at established academic medical centers or IRB-approved research organizations, and involve licensed medical professionals and therapists. They will never ask you to provide your own substance, will provide clear written informed consent documentation, and will not charge you for participation. Be very wary of any "research" that involves fees or asks you to bring substances.

What should I expect during a psilocybin session in a clinical trial?

Clinical trial sessions are conducted in purpose-designed rooms decorated to be comfortable and non-clinical — often with soft furniture, artwork, and music. You take the dose orally, typically a capsule, and then recline on a comfortable couch or bed. Two trained therapists are present throughout the entire session. You are encouraged to keep your eyes closed under an eye mask and use headphones for a curated music playlist. The session typically lasts 6-8 hours. You are never alone. The therapists' role is to provide safety and presence, not to direct your experience.

Can I choose which condition/trial I participate in?

You can search ClinicalTrials.gov for trials matching your situation and interests. You apply to specific trials and go through their specific screening process. You cannot enroll in a trial you do not meet the eligibility criteria for. If you have a specific condition (like depression), you may want to prioritize trials that could offer direct therapeutic benefit. If you are primarily interested in contributing to science, healthy volunteer trials may be appropriate.

How long do the benefits from research-setting psilocybin last?

This varies considerably by individual and condition. The Johns Hopkins and Imperial College trials for depression have shown that antidepressant effects at significant follow-up (6 months, 1 year) remain in a substantial proportion of participants. The 2021 Imperial trial showed effects persisting comparably to 6 weeks of daily SSRIs after just 2 psilocybin sessions. Long-term follow-up studies suggest that for many people, effects are maintained years later, often with continued integration work.

What happens if I have a very difficult experience during the trial?

Difficult experiences are anticipated and planned for in clinical trials. Two trained therapists remain present throughout the entire session and are trained in psychedelic crisis support. Benzodiazepines are available if distress becomes unmanageable. The clinical setting is optimized to minimize distress. Post-session integration therapy specifically addresses any challenging content. Research shows that even participants who rate sessions as difficult often later rate them as among the most meaningful experiences of their lives.

Are there international psilocybin trials outside the US?

Yes. The UK (Imperial College, King's College London), the Netherlands, Canada, Australia, Switzerland, and Israel all have active psilocybin research programs. ClinicalTrials.gov lists many international trials. The WHO International Clinical Trials Registry Platform (who.int/ictrp) is another resource for finding trials outside the US. Participation typically requires being in the country of the trial site for session visits.

What if I don't qualify for a trial but still want safe, legal psilocybin access?

Oregon's Measure 109 created a licensed psilocybin services framework allowing adults 21+ to access psilocybin with a licensed facilitator at approved service centers — no medical diagnosis required. Colorado's Proposition 122 is implementing a similar framework. These are state-regulated (not federally approved) services. Outside Oregon and Colorado, expanded access programs for terminally ill patients exist in some states. Watching clinicaltrials.gov for newly opening trials is the best strategy for most people.